RxDoctor Payments DataLook up a doctor →

Daniel Peterson, MD

Neurological Surgery · Austin, TXNPI 1518027366

Payments from drug & device makers

$5,803,202in general payments, 2019–2025

Across 968 payments — averaging $5995.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alafair Biosciences, Inc.$5.7M
  • Cerapedics Inc.$54K
  • Surgalign Spine Technologies, Inc.$35K
  • Retropsoas Technologies, LLC$9K
  • Abbott$9K
  • Bioventus LLC$9K
  • plus $35K from 24 others
$22,609in research payments, 2019–2025

Across 9 payments — averaging $2512.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bioventus LLC$23K

What the payments were for

  • Consulting fees$397,91290%
  • Speaking & faculty fees$2320%
  • Travel & lodging$14,0413%
  • Food & beverage$29,6097%
  • Education$180%
  • Gifts$3500%
  • Entertainment$1250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,803,202 in reported general payments places this provider in the 95th percentile of 582 neurological surgery providers in Texas.

See all neurological surgery providers in Texas

Medicare billing

Part B allowed, 2024
$229,807
Medicare patients
311
Services billed
871

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MovantikNaloxegol Oxalate21$8,501
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen242$2,304
Methocarbamol190$900
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen54$690
Gabapentin52$507
Meloxicam30$186
Tramadol Hcl50$137
Methylprednisolone25$103
Pregabalin13$103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Redhill Biopharma Inc.Movantik$60$8,50121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 582 neurological surgery providers in Texas.

Other neurological surgery in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →